AU2023411740A1 - Utilization of mesenchymal stem cells or culture supernatant thereof - Google Patents

Utilization of mesenchymal stem cells or culture supernatant thereof

Info

Publication number
AU2023411740A1
AU2023411740A1 AU2023411740A AU2023411740A AU2023411740A1 AU 2023411740 A1 AU2023411740 A1 AU 2023411740A1 AU 2023411740 A AU2023411740 A AU 2023411740A AU 2023411740 A AU2023411740 A AU 2023411740A AU 2023411740 A1 AU2023411740 A1 AU 2023411740A1
Authority
AU
Australia
Prior art keywords
medium
cells
culture
mesenchymal
dipeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023411740A
Other languages
English (en)
Inventor
Itsunari Minami
Chugo RINOIE
Yasutomo YANAGITA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Exosome Therapeutics Inc
Original Assignee
Cell Exosome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Exosome Therapeutics Inc filed Critical Cell Exosome Therapeutics Inc
Publication of AU2023411740A1 publication Critical patent/AU2023411740A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023411740A 2022-12-23 2023-12-22 Utilization of mesenchymal stem cells or culture supernatant thereof Pending AU2023411740A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-207266 2022-12-23
JP2022207266 2022-12-23
PCT/JP2023/046277 WO2024135853A1 (ja) 2022-12-23 2023-12-22 間葉系幹細胞又はその培養上清の利用

Publications (1)

Publication Number Publication Date
AU2023411740A1 true AU2023411740A1 (en) 2025-07-31

Family

ID=91589079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023411740A Pending AU2023411740A1 (en) 2022-12-23 2023-12-22 Utilization of mesenchymal stem cells or culture supernatant thereof

Country Status (4)

Country Link
EP (1) EP4640838A1 (https=)
JP (3) JP7851648B2 (https=)
AU (1) AU2023411740A1 (https=)
WO (1) WO2024135853A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202536166A (zh) * 2023-12-25 2025-09-16 日商武田藥品工業股份有限公司 細胞的培養方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
JP4631463B2 (ja) 2005-02-23 2011-02-16 東亞合成株式会社 新規なカルノシンエステル化合物
EP1930413B1 (en) * 2005-08-23 2011-01-12 Oriental Yeast Co., Ltd. Technique for culture of mesenchymal stem cell utilizing laminin-5
KR100908481B1 (ko) * 2006-04-24 2009-07-21 코아스템(주) 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP2010031004A (ja) 2008-07-04 2010-02-12 Yaizu Suisankagaku Industry Co Ltd 新規イミダゾール誘導体及びその製造方法並びに該イミダゾール誘導体を利用したヒスチジンアミド誘導体の製造方法
JP5590646B2 (ja) 2009-10-08 2014-09-17 国立大学法人大阪大学 ヒト多能性幹細胞用培養基材およびその利用
AU2011213081A1 (en) * 2010-02-02 2012-08-23 University Of Rochester Methods of isolating and culturing mesenchymal stem cells
WO2012137970A1 (ja) 2011-04-08 2012-10-11 国立大学法人大阪大学 改変ラミニンおよびその利用
CN104884468B (zh) 2012-12-28 2018-08-31 国立大学法人大阪大学 附加有胶原结合性分子的改造层粘连蛋白及其利用
CN106559994A (zh) 2014-07-16 2017-04-05 国立大学法人大阪大学 层粘连蛋白片段的细胞培养基质活性增强方法
JP2019131532A (ja) 2017-09-05 2019-08-08 株式会社トクヤマ 酸無水物、および該酸無水物を用いたｌ−カルノシンの製造方法
CN109504649B (zh) * 2017-09-15 2022-06-14 天津小西生物医药科技有限公司 使用兔皮提取物促进细胞增殖的方法
JP2020022433A (ja) 2018-08-01 2020-02-13 東海物産株式会社 イミダゾールジペプチドの製造方法
CN109777771B (zh) * 2019-03-26 2020-08-21 广东先康达生物科技有限公司 原代脐带间充质干细胞的无血清培养基及其使用方法
JPWO2021200744A1 (https=) 2020-03-31 2021-10-07
CN112094812A (zh) * 2020-09-25 2020-12-18 郑州佐爵生物科技有限公司 一种促进骨髓间充质干细胞向神经元细胞分化的方法
KR20220111374A (ko) * 2021-02-02 2022-08-09 연세대학교 산학협력단 골질환의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
WO2024135853A1 (ja) 2024-06-27
JP2025081432A (ja) 2025-05-27
EP4640838A1 (en) 2025-10-29
JPWO2024135853A1 (https=) 2024-06-27
JP7851648B2 (ja) 2026-04-27
JP2026048907A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
US11179420B2 (en) Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject
Bobis et al. Mesenchymal stem cells: characteristics and clinical applications.
EP3081223B1 (en) Method for promoting generation of stem cell-derived exosome by using thrombin
US12478646B2 (en) Umbilical cord-derived adherent stem cells, preparation method therefor, and use thereof
KR20100035648A (ko) 체외 배양 및 증식 자기재생성 집락 형성 세포를 이용한 질환 및 장애 치료방법
EP4155389A2 (en) Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
AU2023411740A1 (en) Utilization of mesenchymal stem cells or culture supernatant thereof
Wang et al. Effect of tumor necrosis factor α on ability of SHED to promote osteoclastogenesis during physiological root resorption
KR20220092880A (ko) 골수 중간엽 줄기세포 유래의 세포 군집 및 이의 제조 방법
CA3278036A1 (en) Utilization of mesenchymal stem cells or culture supernatant thereof
JP5822189B2 (ja) 幹細胞から褐色脂肪細胞への分化誘導促進剤
CN111676190B (zh) 一种干细胞向成软骨分化的诱导剂及其应用
EP2766475A1 (en) Uses of growth and differentiation factor 8 (gdf-8)
KR20100069376A (ko) 성장 인자를 이용한 지방기원 중간엽 줄기세포의 연골세포로의 분화 방법
US20240117301A1 (en) Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent
Osta Effects of Interleukine-17A (Il-17A) and tumor necrosis factor alpha (TNF-α) on osteoblastic differentiation
KR20190047966A (ko) 지방 유래 줄기세포의 사이토카인 분비능 증진 방법
Wang et al. TSG-6 inhibits the NF-κB signaling pathway and promotes the odontogenic differentiation of DPSCs via CD44 in an inflammatory environment
Almashat Gene expression profiles of cytokines during osteogenic differentiation of human gingiva derived mesenchymal stem cells
US20260117175A1 (en) In Vitro Culturing of Cells That Produce or Are Capable of Producing Antibodies
PT2224934E (pt) Utilização de osteoblastos no tratamento de doenças reumatismais inflamatórias
Bobis-Wozowicz et al. Mesenchymal stem cells: characteristics and clinical applications
Li et al. Platelet-Rich Plasma Promotes the Proliferation of Human Muscle Derived Progenitor Cells
JPWO2008099561A1 (ja) 抗菌性ペプチドを用いた細胞増殖促進剤及び該細胞増殖促進剤を含有する無血清培地を用いる細胞増殖促進方法